DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Fareston (Toremifene Citrate) - Summary

 
 



FARESTON SUMMARY

FARESTON (toremifene citrate) Tablets for oral administration each contain 88.5 mg of toremifene citrate, which is equivalent to 60 mg toremifene.

FARESTON is indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors.


See all Fareston indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Fareston (Toremifene)

Who Needs Zoledronic Acid in Early Breast Cancer?
Source: Medscape Hematology-Oncology Headlines [2014.08.29]
Dr. Lidia Schapira describes the role of adjuvant bisphosphonates in early breast cancer as unclear, but suggests that host factors may prove key to efficacy.
Medscape Oncology

To address symptoms following breast cancer surgery, patients need to be treated on an individual basis
Source: Breast Cancer News From Medical News Today [2014.08.28]
For those affected, breast cancer is a dramatic diagnosis. Patients often have to endure chemotherapy and surgery, which, depending on the individual scenario, may mean breast conserving surgery or...

Better classification to improve treatments for breast cancer
Source: Breast Cancer News From Medical News Today [2014.08.28]
Breast cancer can be classified into ten different subtypes, and scientists have developed a tool to identify which is which.

Potential to predict breast cancer outcomes with new biomarker
Source: Breast Cancer News From Medical News Today [2014.08.28]
A protein named p66ShcA shows promise as a biomarker to identify breast cancers with poor prognoses, according to research published ahead of print in the journal Molecular and Cellular Biology.

Palbociclib expanded access program now open to eligible U.S. patients with HR+, HER2- advanced breast cancer
Source: Breast Cancer News From Medical News Today [2014.08.22]
Pfizer Inc. has announced that the company has initiated a multi-center, open-label expanded access program (EAP) in the United States for the investigational CDK 4/6 inhibitor, palbociclib.

more news >>

Published Studies Related to Fareston (Toremifene)

Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer. [2011]
men younger than 80 years... CONCLUSIONS: Toremifene significantly decreased new vertebral fractures in men

Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. [2010.10]
PURPOSE: Androgen deprivation therapy is associated with fracture risk in men with prostate cancer. We assessed the effects of toremifene, a selective estrogen receptor modulator, on fracture incidence in men receiving androgen deprivation therapy during a 2-year period... CONCLUSIONS: Toremifene significantly decreased the incidence of new vertebral fractures in men receiving androgen deprivation therapy for prostate cancer. It also significantly improved bone mineral density, bone turnover markers and serum lipid profiles. Copyright (c) 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial. [2010.07]
OBJECTIVE: Toremifene and tamoxifen have been used for adjuvant therapy in post-menopausal patients with breast cancer in Japan. Dyslipidemias are common in post-menopausal women. However, limited data are available on the effects of these agents on lipid profiles in Japanese patients. The Japan Toremifene Cooperative Study Group has been conducting a Phase III randomized trial of post-menopausal patients with breast cancer. One of its secondary endpoints is to confirm the effects of these agents on serum lipid profiles... CONCLUSIONS: Distinct differences between two selective estrogen receptor modulators on lipids were observed. Toremifene improved lipid profiles, particularly as an enhancer of high-density lipoprotein cholesterol. To a large extent, tamoxifen improved low-density lipoprotein cholesterol levels. The impact of these improved lipid profiles on the risk of cardiovascular diseases needs further confirmation.

Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer. [2010.05.15]
BACKGROUND: Fareston (toremifene) and tamoxifen, both selective estrogen receptor modulators, are therapeutically equivalent treatments for metastatic breast cancer. We hypothesized that toremifene as compared with tamoxifen given as adjuvant therapy for early stage breast cancer would result in equivalent survival with an improved side effect profile, therefore, providing superior therapeutic efficacy... CONCLUSIONS: Women treated with adjuvant hormonal therapy enjoyed excellent DFS and OS. No significant differences were found between treatment with either tamoxifen or toremifene. Treatment of HR-positive patients with either tamoxifen or toremifene is appropriate. (c) 2010 American Cancer Society.

Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. [2010]
gonadotropin-releasing hormone antagonist... CONCLUSIONS: In men with prostate cancer degarelix and leuprolide have similar

more studies >>

Clinical Trials Related to Fareston (Toremifene)

Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer [Terminated]
Protocol 777-CLP-32 is the treatment and survival continuation protocol of Biomed 777-CLP-29, and will continue to compare combined hormonal therapy using the experimental aromatase inhibitor (AI) atamestane combined with the FDA-approved anti-estrogen toremifene (FarestonŽ), to the single agent FDA-approved aromatase inhibitor letrozole (FemaraŽ) for the treatment of advanced breast cancer. The purpose of this study is to determine whether maximal estrogen suppression achieved via the combination of atamestane, plus toremifene (FarestonŽ), is more effective than letrozole (FemaraŽ) in delaying the growth of breast cancer.

The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer [Terminated]
The purpose of this study is to determine whether maximal estrogen suppression achieved via the combination of an experimental drug, atamestane, plus an FDA-approved drug, toremifene (FarestonŽ), is more effective than another approved drug, letrozole (FemaraŽ), in delaying the growth of breast cancer, and whether the side effects of the combined hormonal therapy are different from the side effects of letrozole.

The Effect of Toremifene Treatment to the Magnetic Resonance Imaging (MRI) Findings in Premenstrual Mastalgia [Active, not recruiting]
The purpose of this study is to determine the effect of toremifene treatment to the MRI findings of the breast in women suffering from premenstrual mastalgia.

Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer [Not yet recruiting]
The purpose of this study is to determine whether Toremifene Citrate is effective in reducing the risk of bone fractures in men with prostate cancer who are on Androgen Deprivation Therapy.

Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer [Recruiting]

more trials >>

Reports of Suspected Fareston (Toremifene) Side Effects

Hepatic Function Abnormal (4)White Blood Cell Count Decreased (4)Interstitial Lung Disease (3)Hepatitis Acute (2)Condition Aggravated (2)Bronchiectasis (2)Diarrhoea (2)Respiratory Failure (2)Neoplasm Progression (1)Osteomyelitis (1)more >>


Page last updated: 2014-08-29

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014